NCT06987500View on ClinicalTrials.gov

A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

February 14, 2027

Study Completion Date

August 16, 2027

Conditions
Tumor, Solid
Interventions
DRUG

XNW29016

Oral Medication. The study set 7 dose level cohorts in dose escalation part.

DRUG

XNW29016

Oral Medication

Trial Locations (1)

100021

RECRUITING

17 South Li, Panjiayuan, Chaoyang District, Beijing City., Beijing

Sponsors
All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Evopoint Biosciences Inc.

INDUSTRY